top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem and iTolerance signed a collaboration agreement several months ago to co-develop cell technology as a potential cure for...
Nov 7, 20234 min read
Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx
The patent approval in the US strengthens the company’s global leadership position in the diabetes field Ness Ziona, Israel, June 20th,...
Jun 20, 20234 min read
Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes
Kadimastem Granted European Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes...
May 15, 20233 min read
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
The grant is intended for the joint development of a potential cure for diabetes without the need for chronic suppression of the immune...
May 9, 20235 min read
Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS
IND Approval Allows Commencement of the Multi-Site Clinical Trial and Recruitment of Eligible ALS Patients for Repeated Dosing of...
Mar 19, 20234 min read
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS
The study will Determine if Repeated Dosing of AstroRx® in Three-month Intervals Achieves a Continuous Delay of the Progression of ALS to...
Feb 19, 20235 min read
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
The publication presents the company’s successful phase I/IIa clinical trial in Israel to evaluate the safety, tolerability, and...
Feb 15, 20234 min read
Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
It’s in addition to the company's patents for the product in the US, Europe, Japan and Israel. The patent grant strengthens the company's...
Feb 5, 20234 min read
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
The company's main stakeholders, Prof. Michel Revel and Mr. Julian Ruggeri and the European Alpha Capital Anstalt, expressed confidence...
Jan 9, 20233 min read
Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant
Kadimastem and iTolerance’s Proposed Collaboration to Develop a Potential Cure for Diabetes is Further Strengthened With Receipt of NIS...
Dec 20, 20225 min read
Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes
Cell Selection and Enrichment Technology is Used to Develop IsletRx Treatment for Diabetes in a Third Territory This approval of...
Sep 28, 20224 min read
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
The patent supports the Phase IIa study of AstroRx® for ALS planned to begin in the US in 2023 Ness Ziona, Israel, August 9, 2022 ---...
Aug 9, 20224 min read
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement
The Evaluation Agreement is Towards the Potential Licensing of “Immune Evasive” Cells If the feasibility study is successful, it would be...
Jun 8, 20224 min read
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
Ness Ziona, Israel, May 30, 2022 --- Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS,...
May 30, 20223 min read
Kadimastem Expands R&D Program to Include Multiple Sclerosis
Following positive results from its first clinical study in ALS, Kadimastem Tests The Potential of AstroRx® As A Therapeutic Treatment...
May 18, 20224 min read
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
The Grant will support the Further Development of Cell Therapy Product AstroRx®, for the Treatment of ALS And support the Company’s FDA...
Mar 3, 20223 min read
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
For the Support of Production Scale Up of Astrocyte cells Used to Produce ALS Cell Therapy Treatment AstroRx® in Preparation for Phase...
Dec 13, 20214 min read
ILEX Medical to Invest 10 million NIS ($3.2 million)
ILEX Medical receives options that if exercised would increase this financing round to 21 million NIS ($6.7 million) Kadimastem's Board...
Nov 25, 20215 min read
We rang the TASE bell today!
In honor of the “International Diabetes Awareness Day” and the 100-year anniversary of the discovery of insulin, Kadimastem opened the...
Nov 15, 20211 min read
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
The raise was led by Clover Wolf, Alpha Capital Anstalt and the controlling shareholders of the company, Professor Michel Revel and Mr....
Oct 25, 20214 min read
bottom of page